Efficacy and safety of monoamine reuptake inhibitors in attention deficit hyperactivity disorder: A Bayesian network meta-analysis
-
Published:2024-08
Issue:
Volume:176
Page:403-410
-
ISSN:0022-3956
-
Container-title:Journal of Psychiatric Research
-
language:en
-
Short-container-title:Journal of Psychiatric Research
Author:
Maji Shampa,
Mishra Archana,
Ramasubbu Mathan Kumar,
Mohapatra Debadatta,
Maiti RituparnaORCID
Reference47 articles.
1. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder: results of 2 phase 3, randomized, double-blind, multicenter, placebo-controlled trials;Adler;J. Clin. Psychopharmacol.,2022
2. Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial;Adler;Int. Clin. Psychopharmacol.,2021
3. Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults;Ahmed;Expert Rev. Pharmacoecon. Outcomes Res.,2013
4. Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder;Amiri;Hum. Psychopharmacol.,2012
5. Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder;Arabgol;Eur. Child Adolesc. Psychiatr.,2009